In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations

In VitroActivity of Ceftaroline-Avibactam against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals from 2010 to 2012: Results from the CANWARD Surveillance Study

(2013) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of Ceftaroline-Avibactam Tested against Clinical Isolates Collected from U.S. Medical Centers in 2010-2011

(2013) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase Groups

(2013) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination

(2013) George G. Zhanel et al.   DRUGS

Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases

(2013) David E. Ehmann et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Carbapenemases: Partners in crime

(2013) Karen Bush   Journal of Global Antimicrobial Resistance

In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae

(2011) Z. Aktaş et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Different Carbapenems and Regimens of Administration on Resistance Emergence for Three Isogenic Pseudomonas aeruginosa Strains with Differing Mechanisms of Resistance

(2010) A. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY